Trial Profile
A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Vorinostat (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 14 Jun 2016 Status changed from recruiting to discontinued as per sponsor's request.
- 07 Dec 2008 Planned initiation date changed from 1 Nov 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.
- 21 Nov 2008 New trial record.